DSGN Stock Overview
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.17|
|52 Week High||US$50.50|
|52 Week Low||US$10.89|
|1 Month Change||-39.19%|
|3 Month Change||-24.37%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-73.08%|
Recent News & Updates
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|DSGN||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how DSGN performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DSGN performed against the US Market.
|DSGN Average Weekly Movement||13.7%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: DSGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: DSGN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich’s ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Design Therapeutics Fundamentals Summary
|DSGN fundamental statistics|
Is DSGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DSGN income statement (TTM)|
|Cost of Revenue||US$20.15m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||-85,827.27%|
How did DSGN perform over the long term?See historical performance and comparison
Is Design Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DSGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DSGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DSGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: DSGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DSGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DSGN is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (1.9x).
How is Design Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DSGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DSGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DSGN is forecast to have no revenue next year.
High Growth Revenue: DSGN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DSGN's Return on Equity is forecast to be high in 3 years time
How has Design Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: DSGN is currently unprofitable.
Growing Profit Margin: DSGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DSGN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: DSGN has a negative Return on Equity (-7.23%), as it is currently unprofitable.
How is Design Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: DSGN's short term assets ($395.3M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: DSGN's short term assets ($395.3M) exceed its long term liabilities ($3.3M).
Debt to Equity History and Analysis
Debt Level: DSGN is debt free.
Reducing Debt: DSGN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DSGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DSGN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 105.2% each year
What is Design Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DSGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DSGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DSGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DSGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DSGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
João Siffert (58 yo)
Dr. João Siffert, MD, is Chief Executive Officer and Director at Design Therapeutics, Inc since October 2020 and its President since January 2021. From August 2011 to April 2016, he served as Chief Medical...
CEO Compensation Analysis
Compensation vs Market: João's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Insufficient data to compare João's compensation with company performance.
Experienced Management: DSGN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: DSGN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: DSGN only recently listed within the past 12 months.
Design Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Design Therapeutics, Inc.
- Ticker: DSGN
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$616.942m
- Shares outstanding: 55.23m
- Website: https://www.designtx.com
Number of Employees
- Design Therapeutics, Inc.
- 6005 Hidden Valley Road
- Suite 110
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 23:11|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.